Endo Pharmaceuticals is shaking the personnel tree again, this time in the marketing department. Out is U.S. branded pharma President Joseph Ciaffoni, who joined Endo in August, as former Sanofi exec Patrick Barry moves in.
Barry comes in with a slightly different title—senior VP of U.S. branded pharmaceuticals—with another new exec, Matthew Davis, slotted in as senior VP for research and development, branded pharmaceuticals.
Why the marketing changes now? Endo declined to comment. But a couple of factors likely played into the changes, including a set of new C-level managers and the new course they’ve charted for the specialty pharma company.
Endo announced a top-level overhaul in September, just a month after CEO Rajiv De Silva brought Ciaffoni over from Biogen. De Silva made an abrupt exit, and Endo named its own generics and OTC chief Paul Campanelli to replace him.
Analysts saw the exec changes as a sign that Endo would shift away from De Silva’s acquisition-heavy strategy, which he had honed while president and COO at Valeant. With his departure, market-watchers said Endo would likely put a stronger focus on its roots in specialty brands and generics, which made up more than 60% of revenue in 2015.
Barry’s hire appears to fit with that hypothesis. He joins Endo from Sanofi, where he most recently oversaw sales and marketing activities for branded and generic products in the U.S. and Canada.
The company has also taken another big turn. After facing ruboff from the ongoing controversy over opioid painkillers—which have been among Endo’s top-selling meds—the company cut its 375-rep U.S. branded field corps, in effect sidelining its core pain business. Analysts are speculating that the pain portfolio may be on the block as Endo looks to sell assets to pay down its acquisition debt.
The marketing exec changes also follow the departure of CFO Suketu Upadhyay, who left company in October. Last week, Endo named senior VP of global finance operations Blaise Coleman to take the job; he’d served as interim finance chief since Upadhyay left.
By Beth Snyder Bulik
Source: Fierce Pharma
Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.
The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.
Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.